Federal regulators announced that the shortages of Ozempic and Wegovy have officially ended, with drug manufacturer Novo Nordisk capable of meeting both current and future U.S. demand. Although the injectable diabetes and obesity treatments faced supply challenges since 2022, improvements are now underway, though patients may still experience some disruptions during the transition from manufacturer to pharmacies. Furthermore, compounding pharmacies producing off-brand versions of these drugs will need to cease operations in the upcoming months, as the standard supply is restored. GLP-1 medication sales have surged despite previous access challenges due to insurance.
Shortages of Ozempic and Wegovy have been resolved as Novo Nordisk can meet current U.S. demand, though some supply disruptions may still occur during distribution.
The injectable drugs have been in shortage since 2022, but improvements in supply mean patients can expect better access moving forward.
Compounding pharmacies that made off-brand versions during the shortages must cease production in the coming months as standard supplies become available.
Sales for Ozempic, Wegovy, and other GLP-1 drugs have surged, presenting challenges for patient access due to insurance coverage issues.
Collection
[
|
...
]